Transition from asymptomatic to symptomatic systolic chronic heart failure: rationale and design of TransitionCHF.

ABSTRACT:

Aims

Chronic systolic heart failure (CHF) is a major health burden. A relevant number of patients shows asymptomatic left ventricular dysfunction (ALVSD) before symptomatic CHF or becomes asymptomatic after initiating heart failure therapy. Clinical course, prognosis, and response to pharmacological and device-based treatment are largely unknown in these two distinct groups of patients. Current pharmacological and interventional therapies do neither properly address the underlying pathophysiology nor prevent malignant loss of function. New therapeutic paradigms are needed to stop the progression from asymptomatic to symptomatic heart failure. Key questions are what causes progression of clinically asymptomatic New York Heart Association (NYHA) I heart failure to overt heart failure

SUBMITTER: Sandek A 

PROVIDER: S-EPMC11287358 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature